News | October 25, 2010

Dutch Court Rules in Favor of Occlutech in AGA Patent Case

October 25, 2010 – The Hague, Netherlands ruled in favor of Occlutech, a transcatheter structural heart occluder device maker, in the ongoing patent litigation with AGA Medical. The lawsuit stems from AGA alleging Occlutech’s technology infringes on its Amplatzer transcatheter occluder device patents.

AGA had appealed the court ruling in Occlutech’s favor in 2008. In the new ruling, the appeal court of The Hague saw no reason to change the favorable first instance ruling. The Dutch appeal court decision is similar to the appeals court rulings in the United Kingdom, which were received in mid-2010. The rulings are subject to further appeal by AGA.

Occlutech lost in the German district and appeal courts of Dusseldorf in 2007 and 2008, causing a halt of sales and manufacturing activities in Germany. But the German Supreme Court, (BGH), recently announced that it has allowed Occlutech's appeal. Occlutech expects a final decision in the first half of 2011.

If that case is decided in Occlutech's favor, the company said it plans to seek substantial claims for repayments and damages. Due to the litigation activity, Occlutech has lost revenue, had products destroyed and suffered the cost of litigation leading to potential damage claims in excess EUR 50 million.

AGA was recently purchased by St. Jude Medical.

For more information: www.occlutech.com

Related Content

Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders| March 29, 2017
March 29, 2017 — For patients with...
Dee Dee Wang, Henry Ford Hospital, 3D printing for cardiology, 3-D

Dr. Dee Dee Wang with part of Henry Ford Hospital's collection of 3-D printed hearts used for education and to preplan structural heart procedures.

Feature | 3-D Printing| March 03, 2017
March 3, 2017 — A Henry Ford Hospital study found a 100 percent success rate in left atrial appendage (LAA) occlusion
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders| February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care
News | Cath Lab| January 23, 2017
January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended thr
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Overlay Init